Screener
Rigel Pharmaceuticals
RIGLRigel Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of novel small molecule therapies for hematologic disorders and cancer.
Earnings
Next report
Nov 5, 2026 (In 3 days)Revenue estimate$80.1M
EPS estimate$0.92
Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Rigel Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of novel small molecule therapies for hematologic disorders and cancer. The company targets specific signaling pathways, such as SYK, IDH1, and RET, to address critical disease mechanisms in patients with limited treatment options.
Competitive position
A commercial-stage biotech with a leading position in oral SYK inhibition for ITP and a growing portfolio in targeted oncology.
GeographiesUnited States, Europe, United Kingdom, Japan, South Korea, Canada, Israel
Customer segmentsPatients, Healthcare Providers
Business modelProduct-based, Licensing, R&D
SuppliersContract Manufacturing Organizations, Clinical Research Organizations, In-licensing partners
CustomersSpecialty Distributors, Wholesalers, Healthcare Systems
CountryUnited States of America
Listed2000
Employees147.0
CEORaul R. Rodriguez
SectorHealthcare
IndustryBiotechnology
Websiterigel.com
FilingsSEC EDGAR
FAQ
- What is Rigel Pharmaceuticals's market cap?
- Rigel Pharmaceuticals (RIGL) has a market capitalization of $961.1M and trades on NASDAQ.
- What is Rigel Pharmaceuticals's revenue and profitability?
- Rigel Pharmaceuticals generated $276.8M in trailing twelve-month revenue with net income of $321.9M, representing a net margin of 116.3%. Gross margin stands at 91.4%. The latest reported period is Q2 2026.
- Who are Rigel Pharmaceuticals's competitors?
- Rigel Pharmaceuticals's key competitors include Agios Pharmaceuticals, Nuvation Bio Inc., Amgen, and others. These companies compete in similar markets and product categories.
- Who does Rigel Pharmaceuticals partner with?
- Rigel Pharmaceuticals's notable partners include Eli Lilly and Company, Novo Nordisk, Sanofi SA, and others.
- Where is Rigel Pharmaceuticals headquartered?
- Rigel Pharmaceuticals is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2000.
